Tempus Ai, Inc. · NASDAQ:TEM
Tempus Ai — Technical Presentation (May 2025)
13 slides from Tempus Ai's technical presentation, May 2025
Slide 1: An AI-Enabled Clinical Trial Program’s Impact on Patient Screening and Trial Enrollment in 2024
An AI-Enabled Clinical Trial Program’s Impact on Patient Screening and Trial Enrollment in 2024 Samantha Mallahan, Chelsea Osterman, Danielle Skelly, Michelle Huang, Allison Madera, Sarah Salzman, Li-Pang Huang (Tempus AI, Inc.) Ajeet Gajra (Hematology Oncology Associates of Central New York) Ayed A
Slide 2: Insufficient Accrual Into Oncology Trials Is a Well Established Complex Problem
Insufficient Accrual Into Oncology Trials Is a Well Established Complex Problem Cumbersome regulatory Lack of processes Complex trial available trials criteria Estimated ~5% of oncology patients enroll Lack of Proximity of in oncology trials1 centralized patients to trial sites patient database Pati
Slide 3: Tempus AI is Data-Driven Precision Medicine
Tempus AI is Data-Driven Precision Medicine NGS NOTES MEDICATIONS Tempus AI’s mission is to bring the SCANS LABS DIAGNOSIS power of technology, data, and AI to doctors by building a leading precision medicine platform in the ML world - ultimately helping doctors make better decisions and help DIGITA
Slide 4: The Tempus AI TIME Program
4 The Tempus AI TIME Program ▪ Pre-screening support via technical solutions and research nurse navigators ▪ Standardized trial startup process eases administrative burden ▪ 10-day Just-In-Time (JIT) activation allows providers to open trials in response to patient need ▪ Program highlights: o 40,00
Slide 5: Patient Matching with AI Assistance
Patient Matching with AI Assistance 5 Tempus & 3rd Site Identified EMR Integration 1 NGS & EMR data ingested Party NGS Patients into the TIME platform 2 Trial eligibility criteria coded into the platform & Natural Language Processing models deployed 3 Algorithmic matches identified Over 1.2 million
Slide 6: Clinical Trial Activation
6 Tempus AI TIME Program Clinical Trial Activation Standardized Clinical Trial Agreement for all Central IRB to streamline Rate Card with pre- sites, eliminating regulatory submissions negotiated costs repetitive, prolonged negotiations Just in Time Occurs when a patient has been identified and need
Slide 7: Just in TIME Trial Activation
7 Just in TIME Trial Activation Example Timeline of Patient Enrollment Day 0 Day 1 Day 2 Day 4 Day 5 Day 6 Day 7 Day 10 PI signs Essential Budget, Lab kits ECG Remote SIV Patient Patient rapid documents contract, and delivered machine completed consented enrolled and activation collected and rider f
Slide 8: Patient Matching Data
8 Tempus AI TIME Program Patient Matching Data Tempus Database Trial Criteria 1,281,676 patients 98 Trials ● Continuously receives data 87 TIME sites Jan-Dec 2024 ● Searches for new patients and others with updated 16,625,707 patient TIME Matching Platform 515 trial medical data clinical updates 1,3
Slide 9: Clinical Trial Activation Data
Tempus AI TIME Program Clinical Trial Activation 9 Data Median Total Activation Type Activation Activations Time Median time from JIT activation to first consent Just in Time 82 13 days for interventional trials was 4 days Prospective 104 33.5 days PRESENTED BY: Ajee t Gajr a, MD
Slide 10: Patients Screened & Consented Data
Tempus AI TIME Program Patients Screened & 10 Consented Data Screening and Enrollment Interventional Consent Insights Phase Most Common Nurse screened patients 35,912 Breakdown Cancer Types 1 ● Breast Interventional matches 5,034 2 ● NSCLC ● CRC Multi- 3 Interventional consents 225 ● Prostate Phase
Slide 11: AI Facilitates Large-Scale Clinical Trial Enrollment
11 AI Facilitates Large-Scale Clinical Trial Enrollment Rapid Next Steps Activation Used patient data Average of 1.57 JIT & prospective Employing LLMs to & trial criteria to consents per day activations improve matching generate matches over 1 year demonstrated quality and Tempus TIME rapid trial in
Slide 12: Authors & Acknowledgements
Authors & Acknowledgements Samantha Mallahan, Chelsea Osterman, Danielle Skelly, Michelle Huang, Allison Madera, Sarah Salzman, Li-Pang Huang (Tempus AI, Inc.) Ajeet Gajra (Hematology Oncology Associates of Central New York) Ayed Ayed(Cancer Specialists of North Florida) Jay Carlson (Mercy Health) R
Slide 13: How AI Helped Clinical Trials Find and Enroll Patients in 2024
How AI Helped Clinical Trials Find and Enroll Patients 13 in 2024 What did this research tell us? ● The Tempus AI TIME program provides enhanced patient pre-screening and streamlines study start-up for oncology clinical trials, resulting in increased trial enrollment Who does this research impact? ●